MDM2 and cancer: Thus, reactivation of p53 becomes a potential strategy for cancer treatment [22–25] For instance, a p53-MDM2 inhibitor, RG7388, activates p53 signaling pathway by selectively blocking p53-MDM2 binding, exhibiting encouraging anti-cancer efficacy in several different clinical trials [26, 27].